Latest Safety News

Invion Limited launches a Loyalty Option entitlement offer aimed at raising up to $16 million to support its advancing cancer clinical trials, including a promising anogenital cancer study with Peter MacCallum Cancer Centre.

Macarthur Minerals has relaunched a renounceable rights issue to raise nearly A$2 million, fully underwritten by Gold Valley, aiming to fund its Lake Giles Iron Project and strengthen its balance sheet.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.

NexGen Energy has secured regulatory approval for a significant infrastructure upgrade at its Rook I uranium project, setting the stage for expanded exploration and operational efficiency in 2025.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Capricorn Metals has closed out its last gold hedging contract, becoming fully exposed to gold price fluctuations while securing downside protection through put options. This strategic move positions the company to fund growth projects without additional debt or mandatory hedging.

GenusPlus Group has landed a $130 million contract to upgrade NBN’s Fibre to the Node network across Western Australia, targeting 22,000 properties over the next 3.5 years.